Early and unrestricted access to high|efficacy disease|modifying ...

Early and unrestricted access to high-efficacy disease-modifying ...

Early intervention with high-efficacy disease-modifying therapy (HE DMT) may be the best strategy to delay irreversible neurological damage and progression ...

Early and unrestricted access to high-efficacy disease-modifying ...

Early intervention with high-efficacy disease-modifying therapy (HE DMT) may be the best strategy to delay irreversible neurological damage ...

[PDF] Early and unrestricted access to high-efficacy disease ...

Early and unrestricted access to HE DMTs with a positive benefit–risk profile and a reasonable value proposition will provide the freedom of choice for an ...

(PDF) Early and unrestricted access to high-efficacy disease ...

PDF | Early intervention with high-efficacy disease-modifying therapy (HE DMT) may be the best strategy to delay irreversible neurological damage and.

Early use of high-efficacy disease‑modifying therapies makes the ...

You have full access to this open access article. Journal of ... access for MS patients, especially in the earliest phases of the disease.

Early High Efficacy Treatment in Multiple Sclerosis Is the Best ...

In 2006, natalizumab was approved as the first high efficacy disease modifying ... This is an open-access article distributed under the terms of ...

Early use of high-efficacy therapies in multiple sclerosis in the ...

... disease activity and disability [124, 127]. As an alternative, early and unrestricted access to HETs and diagnostic and monitoring tests can ...

Review article Cost, efficacy, and safety comparison between early ...

Filippi et al. Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple ...

Early and unrestricted access to high-efficacy disease-modifying ...

Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. https ...

An argument for broad use of high efficacy treatments in early ...

Open Access Letter to the Editor. An argument for broad use of high ... Beyond lines of treatment: embracing early high-efficacy disease-modifying ...

Long-term clinical outcomes in patients with multiple sclerosis who ...

Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple ...

(PDF) Early use of high-efficacy disease‑modifying therapies makes ...

Access to this full-text is provided by Springer Nature. Learn more. Content available from Journal of Neurology. This content is subject to ...

Factors associated with the initiation of high-efficacy disease ...

19. Filippi, M. ∙ Danesi, R. ∙ Derfuss, T. ... Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for ...

Initial high-efficacy disease-modifying therapy in multiple sclerosis

... early high-efficacy treatment in patients with high disease activity. ... In Denmark, the health care system is government-financed with free and equal access for ...

Early and unrestricted access to high-efficacy disease-modifying ...

Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple ...

Disease-modifying therapies in managing disability worsening in ...

High-efficacy disease-modifying therapies have been proven to ... Log in, subscribe or purchase for full access. Get Access. References.

Timing of high-efficacy therapy for multiple sclerosis - The Lancet

... (early) or 4–6 years (late) after clinical disease onset. We matched patients ... Log in, subscribe or purchase for full access. Get Access. References. 1 ...

Influence of physicians' risk perception on switching treatments ...

Derfuss, et al. Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple ...

Correction to: Early use of high-efficacy disease-modifying therapies ...

... First without Open Access. After publication in volume 269, issue 10, pages 5382–5394 the author decided to opt for Open Choice and to make the article an ...

Paradigm shifts: Early initiation of high-efficacy disease-modifying ...

Free access. Editorial. First published online September 2, 2021. Paradigm shifts: Early initiation of high-efficacy disease-modifying treatment in multiple ...